Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM), On Deck Capital Inc. (NYSE:ONDK) and Globalstar Inc. (NYSEMKT:GSAT) got a strong start to the week on Wall Street. iDreamSky Technology Ltd. (NASDAQ:DSKY), Seventy Seven Energy Inc. (NYSE:SSE) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) experienced quite the opposite.
Sign up for our free newsletter
Third Point's Dan Loeb discusses their new positions in a letter to investor reviewed by ValueWalk. Stay tuned for more coverage. Loeb notes some new purchases as follows: Third Point’s investment in Grab is an excellent example of our ability to “lifecycle invest” by being a thought and financial partner from growth capital stages to Read More
On Deck Capital Surges
[drizzle]
Bellicum Pharmaceuticals ended the day with a gain of +8.41%, hitting $24.75. The biotech company is up a modest +7.42% year-to-date and has a small allocation in George Soros’ public equity portfolio.
On Deck Capital Inc. surged +8.19% this Monday and is up +24.78% over the past five days. The small business lending platform can be found in the Tiger Global portfolio – in Q4, the hedge fund disclosed 6.35 million shares. Leon Cooperman has a stake in the company as well.
Globalstar Inc. reached market close priced at $3.30, meaning a +7.14% gain this Monday. Last week, news broke that the company is nearing approval for a mobile service. This one is another Soros pick.
iDreamSky Plunges on Ratings Downgrade, Investigation
iDreamSky Technology plunged -33.27% to $7.22 – just cents away from its 52-week low of $7.03. Stifel analyst George Askew has downgraded his rating of the stock from a buy to a hold, and news broke today of an investigation on behalf of company investors. Tiger Global and George Soros have positions in the firm.
Carl Icahn holding Seventy Seven Energy tumbled -15.57% today. Since splitting from Chesapeake Energy last June, the stock has declined -87.51%. It posted quarterly earnings at the start of the month, missing EPS expectations by $0.43. It is worth noting that to some, the stock looks undervalued.
Progenics Pharmaceuticals Inc. fell -12.55%, ending the day priced at $6.20, after reporting quarterly earnings. The stock, a Julian Robertson pick, is down -18.06% YTD.
[/drizzle]